STOCK TITAN

ZyVersa Therapeutics Inc - ZVSA STOCK NEWS

Welcome to our dedicated news page for ZyVersa Therapeutics (Ticker: ZVSA), a resource for investors and traders seeking the latest updates and insights on ZyVersa Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ZyVersa Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ZyVersa Therapeutics's position in the market.

Rhea-AI Summary
ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA) is making significant progress with its Cholesterol Efflux MediatorTM VAR 200 and Inflammasome ASC Inhibitor IC 100. The company is set to begin a Phase 2a clinical trial for diabetic kidney disease and plans to submit an IND for IC 100 by the end of 2024. Financially, ZyVersa reported a net loss of $98.3 million for 2023, primarily due to impairments in research and development. Despite this, the company remains optimistic about its future prospects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.96%
Tags
earnings
-
Rhea-AI Summary
ZyVersa Therapeutics, Inc. receives IRB approval for Phase 2a clinical trial of Cholesterol Efflux Mediator VAR 200 in patients with diabetic kidney disease, marking a significant milestone in the development of first-in-class drugs for renal diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.79%
Tags
clinical trial
-
Rhea-AI Summary
ZyVersa Therapeutics, Inc. is developing Inflammasome ASC Inhibitor IC 100 to combat chronic inflammatory diseases, a leading cause of death globally. The company's CEO will speak at Benzinga's Virtual Healthcare Summit 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.3%
Tags
conferences
Rhea-AI Summary
ZyVersa Therapeutics, Inc. (ZVSA) announced the development of Inflammasome ASC Inhibitor IC 100 to target damaging inflammation associated with obesity and other conditions. The company raised $2.7 Million from existing investors' exercise of warrants, influenced by positive news in the inflammasome inhibitor sector.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10%
Tags
none
-
Rhea-AI Summary
ZyVersa Therapeutics, Inc. highlights data published in Nature reinforcing the rationale for their Inflammasome ASC Inhibitor IC 100 to combat damaging inflammation associated with obesity and its complications. The drug aims to inhibit inflammasomes and ASC specks to attenuate systemic release of inflammatory cytokines and cell death, potentially offering a therapeutic option for metabolic disorders and cancers linked to obesity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.26%
Tags
none
-
Rhea-AI Summary
ZyVersa Therapeutics, Inc. announces availability of a new white paper titled 'Inflammasome ASC Inhibitor IC 100, Promising Therapeutic Potential For Neurological Diseases'. The white paper highlights preclinical research showing strong proof-of-concept for the drug in various neurological conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.64%
Tags
none
Rhea-AI Summary
ZyVersa Therapeutics, Inc. highlights data from a review article showing the role of inflammasomes in neurological diseases. Their drug IC 100 targets ASC specks to block damaging inflammation, with promising potential for conditions like Alzheimer's and multiple sclerosis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.14%
Tags
none
-
Rhea-AI Summary
ZyVersa Therapeutics, Inc. is a clinical stage specialty biopharmaceutical company developing first-in-class drugs for the treatment of renal and inflammatory diseases with high unmet medical needs. The company is advancing a pipeline of drug candidates with multiple programs built around two proprietary technologies – Cholesterol Efflux Mediator™ VAR 200 for treatment of kidney diseases, and Inflammasome ASC Inhibitor IC 100 for treatment of multiple CNS and peripheral inflammatory diseases. The CEO, Stephen C. Glover, will provide a corporate update at the BIO CEO & Investor Conference, discussing upcoming development milestones for the Phase 2a clinical trial in patients with diabetic kidney disease and the completion of the preclinical program for Inflammasome ASC Inhibitor IC 100.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.48%
Tags
conferences
-
Rhea-AI Summary
ZyVersa Therapeutics highlights a study linking NLRP3 inflammasome activation to insulin resistance and metabolic complications in obese children. The company is developing Inflammasome ASC Inhibitor IC 100 to address this issue.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.32%
Tags
none
Rhea-AI Summary
ZyVersa Therapeutics, Inc. announces the publication of a scientific paper in Alzheimer's & Dementia: Translational Research & Clinical Interventions, demonstrating the role of the inflammasome/ASC speck pathway in synaptic degeneration in Alzheimer’s Disease. The paper highlights the potential of ZyVersa’s Inflammasome ASC Inhibitor IC 100 in targeting ASC specks to block damaging inflammation in the central nervous system and peripheral tissues.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.69%
Tags
none
ZyVersa Therapeutics Inc

Nasdaq:ZVSA

ZVSA Rankings

ZVSA Stock Data

5.70M
4.00M
0.83%
3%
8.51%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Weston

About ZVSA

variant pharmaceuticals is an orphan drug company leveraging advanced proprietary technologies to develop best-in-class drugs for patients with rare diseases. our accomplished leadership team, each with more than 15 years of demonstrated success in the biopharmaceutical and medical industries, focuses on assuring that our development efforts serve the needs of all our stakeholders: patients, health care providers, payors, and our investors. our evolving product pipeline is targeted to the $100+ billion orphan drug market. our lead orphan drug candidate is hydroxypropyl beta cyclodextrin (hpβcd) for chronic treatment of two orphan indications, var 200: focal segmental glomerulosclerosis (fsgs) and var 300: alport syndrome (as). both of these conditions are rare progressive forms of kidney disease associated with accumulation of cholesterol and lipids, contributing to impaired kidney function, ultimately leading to dialysis and/or kidney transplantation. hpβcd entraps and removes lipids